vTv Therapeutics (VTVT) Stock Statistics & Valuation Metrics

vTv Therapeutics has a market cap or net worth of $70.84M. The enterprise value is $72.61M.

vTv Therapeutics has 2,617,215 shares outstanding. The number of shares has decreased by -2.65% in one year.

vTv Therapeutics’s return on equity (ROE) is -1.51 and return on invested capital (ROIC) is -72.70%.

The current PE Ratio of vTv Therapeutics is ―. vTv Therapeutics’s PEG ratio is ―.

In the last 12 months, vTv Therapeutics had revenue of 1.02M and earned -18.46M in profits. Earnings per share was -3.20.

In the last 12 months, operating cash flow was -22.02M and capital expenditures 0.00, giving a free cash flow of -22.02M billion.

vTv Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

vTv Therapeutics upcoming earnings date is Nov 6, 2025, Before Open (Confirmed).

vTv Therapeutics as a current ratio of 7.34, with Debt / Equity ratio of 2.86%

In the past 12 months, vTv Therapeutics has paid 100.00K in taxes.

vTv Therapeutics EV to EBITDA ratio is -1.92, with an EV/FCF ratio of -1.70.

vTv Therapeutics has $25.92M in cash and marketable securities with $79.00K in debt, giving a net cash position of $25.84M billion.

Gross margin is -211.76%, with operating margin of -2377.58%, and net profit margin of -1815.34%.

The average price target for vTv Therapeutics is $36.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy